• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques.

作者信息

Li Rong, Ma Xiancai, Deng Jieyi, Chen Qier, Liu Weiwei, Peng Zhilin, Qiao Yidan, Lin Yingtong, He Xin, Zhang Hui

机构信息

Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.

Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.

出版信息

Cell Mol Immunol. 2021 Apr;18(4):1058-1060. doi: 10.1038/s41423-021-00641-8. Epub 2021 Feb 12.

DOI:10.1038/s41423-021-00641-8
PMID:33580167
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7880638/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dcf/7880638/ae9ee464e8d0/41423_2021_641_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dcf/7880638/ae9ee464e8d0/41423_2021_641_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dcf/7880638/ae9ee464e8d0/41423_2021_641_Fig1_HTML.jpg

相似文献

1
Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques.康复期新冠患者和接受RBD纳米颗粒疫苗接种的恒河猴的血清对新型突变体B.1.1.7和501Y.V2的中和效率差异。
Cell Mol Immunol. 2021 Apr;18(4):1058-1060. doi: 10.1038/s41423-021-00641-8. Epub 2021 Feb 12.
2
Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies.新出现的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体降低了对康复期血清和单克隆抗体的中和敏感性。
Cell Mol Immunol. 2021 Apr;18(4):1061-1063. doi: 10.1038/s41423-021-00648-1. Epub 2021 Feb 25.
3
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).由SARS-CoV-2 501Y.V2（B.1.351）引发的交叉反应性中和抗体反应
N Engl J Med. 2021 Jun 3;384(22):2161-2163. doi: 10.1056/NEJMc2104192. Epub 2021 Apr 7.
4
Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.利用具有 SARS-CoV-2 刺突蛋白的水疱性口炎病毒评估 SARS-CoV-2 中和抗体。
Virol J. 2021 Jan 12;18(1):16. doi: 10.1186/s12985-021-01490-7.
5
Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.既往感染与疫苗接种产生针对 SARS-CoV-2 变异株的中和抗体效力。
mBio. 2021 Dec 21;12(6):e0265621. doi: 10.1128/mBio.02656-21. Epub 2021 Dec 7.
6
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.德尔塔变异株对抗体中和的敏感性降低。
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.
7
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.奥密克戎变异株对 SARS-CoV-2 表现出明显的抗体逃逸。
Nature. 2022 Feb;602(7898):676-681. doi: 10.1038/s41586-021-04388-0. Epub 2021 Dec 23.
8
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.SARS-CoV-2 从高中和性的 COVID-19 恢复期血浆中逃逸。
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36). doi: 10.1073/pnas.2103154118.
9
Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.疫苗诱导产生的抗体水平与针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其变体的中和活性之间的相关性。
Clin Transl Med. 2021 Dec;11(12):e644. doi: 10.1002/ctm2.644.
10
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies.全面绘制影响多克隆人血浆抗体识别的 SARS-CoV-2 受体结合域突变图谱。
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6. doi: 10.1016/j.chom.2021.02.003. Epub 2021 Feb 8.

引用本文的文献

1
B.1.1.7 (Alpha) variant is the most antigenic compared to Wuhan strain, B.1.351, B.1.1.28/triple mutant and B.1.429 variants.与武汉毒株、B.1.351、B.1.1.28/三重突变株和B.1.429变体相比，B.1.1.7（阿尔法）变体的抗原性最强。
Front Microbiol. 2022 Aug 12;13:895695. doi: 10.3389/fmicb.2022.895695. eCollection 2022.
2
COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity.疫苗实施期间的 COVID-19 退出策略：在社交距离和群体免疫之间取得平衡。
Arch Virol. 2022 Sep;167(9):1773-1783. doi: 10.1007/s00705-022-05495-7. Epub 2022 Jun 20.
3
An issue of concern: unique truncated ORF8 protein variants of SARS-CoV-2.

本文引用的文献

1
SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity.SARS-CoV-2 刺突蛋白 D614G 突变增加了病毒粒子刺突密度和感染力。
Nat Commun. 2020 Nov 26;11(1):6013. doi: 10.1038/s41467-020-19808-4.
2
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo.SARS-CoV-2 D614G 变异株在体外具有高效复制能力，并可在体内有效传播。
Science. 2020 Dec 18;370(6523):1464-1468. doi: 10.1126/science.abe8499. Epub 2020 Nov 12.
一个值得关注的问题：SARS-CoV-2 的独特截断 ORF8 蛋白变异体。
PeerJ. 2022 Mar 21;10:e13136. doi: 10.7717/peerj.13136. eCollection 2022.
4
Leishmaniac Quest for Developing a Novel Vaccine Platform. Is a Roadmap for Its Advances Provided by the Mad Dash to Produce Vaccines for COVID-19?利什曼病疫苗研发的探索。为新冠病毒疫苗的疯狂研发所提供的进展路线图能否成为其前进的指引？
Vaccines (Basel). 2022 Feb 7;10(2):248. doi: 10.3390/vaccines10020248.
5
Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants.研发针对 SARS-CoV-2 德尔塔及其他变体具有广谱中和作用的受体结合域（RBD）偶联纳米颗粒疫苗。
Adv Sci (Weinh). 2022 Apr;9(11):e2105378. doi: 10.1002/advs.202105378. Epub 2022 Feb 10.
6
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2.一种二价纳米颗粒疫苗对 SARS-CoV-2 的变异株表现出强大的交叉保护作用。
Cell Rep. 2022 Jan 18;38(3):110256. doi: 10.1016/j.celrep.2021.110256. Epub 2021 Dec 23.
7
The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries.血清学检测在拉丁美洲国家 COVID-19 免疫政策中的作用。
Viruses. 2021 Nov 29;13(12):2391. doi: 10.3390/v13122391.
8
Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route.野生型小鼠感染 SARS-CoV-2 B.1.351 变异株提示可能存在新的跨种传播途径。
Signal Transduct Target Ther. 2021 Dec 14;6(1):420. doi: 10.1038/s41392-021-00848-1.
9
Clinical characteristics of COVID-19 patients in Xiaogan, China: comparison between recent imported cases and earlier local cases.中国孝感新冠肺炎患者的临床特征：近期输入病例与早期本地病例的比较。
Am J Transl Res. 2021 Oct 15;13(10):11999-12005. eCollection 2021.
10
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）监测的下一阶段：实时分子流行病学
Nat Med. 2021 Sep;27(9):1518-1524. doi: 10.1038/s41591-021-01472-w. Epub 2021 Sep 9.